Thus, [18F]PI-2620 is currently being evaluated in several clinical trials to define its pharmacokinetic properties and its metabolic profile in humans to confirm its suitability for imaging pathological tau aggregates/aggregate folds in AD and non-AD tauopathies in vivo. The gene discussed is MAPT; the disease is Alzheimer disease.